Source: Eur Respir Rev 2015; 24: 411-419
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cappelli Susanna, Bellando Randone Silvia, Camiciottoli Gianna, De Paulis Amato, Guiducci Serena, Matucci-Cerinic Marco. Interstitial lung disease in systemic sclerosis: where do we stand?. Eur Respir Rev 2015; 24: 411-419

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease; where do we stand without histopathology? Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 Immunosuppression for interstitial lung disease in systemic sclerosis}, Source: Eur Respir Rev 2013; 22: 236-243 Year: 2013 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Interstitial lung disease: ?course report Source: Breathe, 16 (3) 200075; 10.1183/20734735.0075-2020 Year: 2020 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Respiratory function in systemic sclerosis patients Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014